dr. morepen limited
Tender Performance & Track Record
Company Overview
Tender Performance
Data for 01 April 2024 to 02 November 2025
Total Bids / Contract Value
Qualified Bids / Q Rate
Total Wins / Win Value
Wins Rate / Q-W Rate
Detailed Performance Analysis
Top Bid Competitors
Companies that frequently compete with you in the same tenders — ranked by their total win value.You applied for 2 bids — Company 688b6fdc48bb3821b2fb3ed8 appeared in 2 of them.
DR. MOREPEN LIMITED
DR. MOREPEN LIMITED
Financial Details
Registered Office
409, Antriksh Bhawan 22, K.G. MargNA-New Delhi-Delhi-110001-India
Industry Classification
Manufacturing (Metals & Chemicals, and products thereof)
Company Type
Market Information
Transform Your Tender Process
Join thousands of businesses winning more tenders
Smart Alerts
Get AI-powered tender recommendations
Market Intel
Track competitor bidding patterns
Email Reports
Weekly detailed analytics reports
Download Hub
Export tender data in bulk format
Smart Tracking
Never miss important deadlines
& Much More...
Discover all premium features with your trial
"TendersAi transformed our bidding process. We've increased our win rate by 40% and saved countless hours."
Historical Performance
7-year trend analysis (2018-2025)
Company Overview (1 Apr 2018-31 Mar 2025))
Total Bids
0
Contract Value
₹0
L1 Bids
0
Recent Win Rate
0.0%
Performance Analytics
DR. MOREPEN LIMITED: Government Tender Performance Analysis
DR. MOREPEN LIMITED is beginning to establish its presence in India's government tender ecosystem with initial participation. This analysis examines DR. MOREPEN LIMITED's early tender participation, technical qualification approach, and emerging procurement strategy from April 2018 to March 2025.
Executive Summary
As of March 31, 2025, DR. MOREPEN LIMITED has participated in 0 tenders, reflecting an exploratory phase in engaging with government procurement opportunities. With 0 wins recorded, their win rate stands at 0.0%. Financial health assessment using TenderAI scoring components places the company in the 'Critical' category, with a score of 22.5/100. This score takes into account factors like win rate, contract value, bid efficiency, growth, and consistency. Despite the current metrics, DR. MOREPEN LIMITED demonstrates an interest in the Indian pharmaceutical sector tender landscape. The primary focus for strategic improvement lies in enhancing bid competitiveness and aligning tender participation with core competencies.
Financial Performance Analysis
Yearly Trends: From FY 2018-19 to FY 2024-25, DR. MOREPEN LIMITED's tender participation has remained limited, with no bids recorded across these fiscal years. This indicates a consistent, but minimal, engagement with government tenders during this period. The absence of bid activity across multiple fiscal years presents a challenge for longitudinal financial performance analysis.
Quarterly Patterns: Given the absence of bids over the analyzed period, there are no discernible quarterly patterns to report. Future performance should be evaluated on a quarterly basis once DR. MOREPEN LIMITED increases its tender participation.
Bid Distribution: From April 2023 to March 2024, DR. MOREPEN LIMITED did not submit any bids across various price ranges. The absence of bids in different price brackets suggests a need for DR. MOREPEN LIMITED to explore diverse tender opportunities to potentially improve its market presence.